Molecular Analysis of HS-111 and 3HS1 Variations in β-Thalassemia Intermedia Patients with High Levels of HbF
Cell Journal (Yakhteh), 2010•celljournal.org
Objective: To study the possible association between high levels of fetal haemoglobin (HbF)
in β-thalassemia intermedia patients and HS-111 and 3HS1 sequence variations. Materials
and Methods: In this study the 3'HS-1 and HS-111 regions of 30 ß-thalassaemia intermedia
patients (ß°/ß°) with high levels of HbF 21 ß-thalassemia major patients and 40 normal
Iranian individuals were analyzed by single-strand conformation polymorphism (SSCP) and
polymerase chain reaction (PCR) sequencing. Results: Two nucleotide variations in …
in β-thalassemia intermedia patients and HS-111 and 3HS1 sequence variations. Materials
and Methods: In this study the 3'HS-1 and HS-111 regions of 30 ß-thalassaemia intermedia
patients (ß°/ß°) with high levels of HbF 21 ß-thalassemia major patients and 40 normal
Iranian individuals were analyzed by single-strand conformation polymorphism (SSCP) and
polymerase chain reaction (PCR) sequencing. Results: Two nucleotide variations in …
Objective
To study the possible association between high levels of fetal haemoglobin (HbF) in β-thalassemia intermedia patients and HS-111 and 3`HS1 sequence variations.
Materials and Methods
In this study the 3' HS-1 and HS-111 regions of 30 ß-thalassaemia intermedia patients (ß°/ß°) with high levels of HbF 21 ß-thalassemia major patients and 40 normal Iranian individuals were analyzed by single-strand conformation polymorphism (SSCP) and polymerase chain reaction (PCR) sequencing.
Results
Two nucleotide variations in 3' HS111 (-21A>G) and 3`HS1 (179C>T) were identified. The most frequent sequence variation was 3' HS111 (-21A) in the intermedia patients and 3`HS111 (-21G) in the major thalassemia patients. In contrast to the 3`HS1 marker both 3'HS111 A and G variants showed a correlation with each studied group.
Conclusion
The HS111 marker in conjunction with other parameters could be used as appropriate genetic markers to discriminate β-thalassemia intermedia patients (β°/β°) with high levels of HbF from β-thalassemia major patients.
celljournal.org